

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Larotrectinib for treating NTRK fusion-positive advanced solid tumours [ID1299]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|-------------------------------------------------------------------------------------------------------------------------------|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|-------------------------------------------------------------------------------------------------------------------------------|

No potential equality issues were identified during the scoping process.

- | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<p>The company submission raised a potential equity issue that patients should have equity of access while health technology assessment methods adapt to the challenges inherent in appraising histology independent technologies. The committee considered that the NICE single technology appraisal process was appropriate for appraising larotrectinib and that the uncertainties associated with the trial design and multiple comparators had been appropriately accounted for in its decision making. This was not considered to be an equality issue for the technology under assessment.</p>

<p>Additionally, an expert statement mentioned that there may be issues relating to accessing genomic testing required to identify NTRK fusions in order to use larotrectinib. This is because genomic testing is currently being established as a national service. The committee considered that any variation in access to genomic testing will likely be resolved in the next 1 to 2 years.</p>

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other potential equality issues were identified.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Section 3.33 of the Appraisal consultation document.

Approved by Associate Director (name): ...Linda Landells.....

Date: 10 Jan 2020

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No additional potential equality issues were raised during consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

An expert statement mentioned that there may be issues relating to accessing genomic testing required to identify NTRK fusions in order to use larotrectinib. This is because genomic testing is currently being established as a national service. The committee considered that any variation in access to genomic testing will likely be resolved in the next 1 to 2 years.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified

in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
No.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Section 3.33 of the final appraisal determination

Approved by Associate Director (name): Jasdeep Hayre

Date: 19/03/2020

Final appraisal determination

(when no ACD was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

[Insert response here]

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

[Insert response here]

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

[Insert response here]

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

[Insert response here]

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

[Insert response here]

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

[Insert response here]

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

[Insert response here]

Approved by Associate Director (name):

Date: [xx/xx/year]